Su Y, et al. - Researchers performed this investigation assessing the utility of plasma cell free DNA (cfDNA) as a biomarker to determine tumor burden and minimal residual disease (MRD) of neuroblastoma (NB) patients during chemotherapy. Recruiting a total of 58 NB patients from July 2016 to December 2017, they identified well response in 65.5% of NB kids. NB patients with partial remission (PR) showed down-regulation of cfDNA, neuron-specific enolase (NSE), and lactate dehydrogenase (LDH) levels consistently when compared to those with stable disease (SD). As per findings, tumor burden and MRD of NB could be evaluated with the dynamic change of cfDNA as a surrogate biomarker during early and intermediate therapy periods.